DE60018554T2 - Arzneimittel zur förderung der neuronalen zelldifferenzierung, die cyclische glycerophosphate und deren analoga enthalten - Google Patents

Arzneimittel zur förderung der neuronalen zelldifferenzierung, die cyclische glycerophosphate und deren analoga enthalten Download PDF

Info

Publication number
DE60018554T2
DE60018554T2 DE60018554T DE60018554T DE60018554T2 DE 60018554 T2 DE60018554 T2 DE 60018554T2 DE 60018554 T DE60018554 T DE 60018554T DE 60018554 T DE60018554 T DE 60018554T DE 60018554 T2 DE60018554 T2 DE 60018554T2
Authority
DE
Germany
Prior art keywords
cyclic
cgp
phenyl
use according
cpp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60018554T
Other languages
German (de)
English (en)
Other versions
DE60018554D1 (de
Inventor
Meir Shinitzky
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yeda Research and Development Co Ltd
Original Assignee
Yeda Research and Development Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Research and Development Co Ltd filed Critical Yeda Research and Development Co Ltd
Publication of DE60018554D1 publication Critical patent/DE60018554D1/de
Application granted granted Critical
Publication of DE60018554T2 publication Critical patent/DE60018554T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE60018554T 1999-03-25 2000-03-24 Arzneimittel zur förderung der neuronalen zelldifferenzierung, die cyclische glycerophosphate und deren analoga enthalten Expired - Fee Related DE60018554T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL12917899 1999-03-25
IL12917899A IL129178A0 (en) 1999-03-25 1999-03-25 Induction of nerve generation
PCT/IL2000/000185 WO2000057865A2 (en) 1999-03-25 2000-03-24 Pharmaceutical compositions comprising cyclic glycerophosphates and analogs thereof for promoting neural cell differentiation

Publications (2)

Publication Number Publication Date
DE60018554D1 DE60018554D1 (de) 2005-04-14
DE60018554T2 true DE60018554T2 (de) 2006-04-13

Family

ID=11072645

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60018554T Expired - Fee Related DE60018554T2 (de) 1999-03-25 2000-03-24 Arzneimittel zur förderung der neuronalen zelldifferenzierung, die cyclische glycerophosphate und deren analoga enthalten

Country Status (16)

Country Link
US (1) US6914056B1 (enExample)
EP (1) EP1162959B1 (enExample)
JP (1) JP2002540146A (enExample)
KR (1) KR20010112364A (enExample)
CN (1) CN1348375A (enExample)
AT (1) ATE290385T1 (enExample)
AU (1) AU768911B2 (enExample)
BR (1) BR0009296A (enExample)
CA (1) CA2368597A1 (enExample)
DE (1) DE60018554T2 (enExample)
HK (1) HK1042038A1 (enExample)
IL (1) IL129178A0 (enExample)
MX (1) MXPA01009650A (enExample)
NZ (1) NZ514525A (enExample)
RU (1) RU2247557C2 (enExample)
WO (1) WO2000057865A2 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69912808T2 (de) 1999-12-08 2004-09-30 Centre National De La Recherche Scientifique (C.N.R.S.) Verwendung von Hymenialdisin und dessen Derivaten zur Herstellung therapeutischer Mittel
JP4836345B2 (ja) * 2001-04-13 2011-12-14 きみ子 室伏 環状ホスファチジン酸誘導体を含む神経細胞の生存促進剤
JP4815063B2 (ja) * 2001-04-13 2011-11-16 きみ子 室伏 環状ホスファチジン酸を含むグリア細胞の増殖、分化及び／又は生存の促進のための薬剤
IL148668A0 (en) * 2002-03-13 2002-09-12 Yeda Res & Dev Derivatives of 1,3-cyclic propandiol phosphate and their action in differentiation therapy
IL148665A0 (en) * 2002-03-13 2002-09-12 Yeda Res & Dev Derivatives of 1,3-cyclic propandiol phate and their action as cell stimulants
AU2003220521A1 (en) * 2002-03-27 2003-10-13 Smithkline Beecham Corporation Methods of treatment with lxr modulators
JP4162927B2 (ja) 2002-06-11 2008-10-08 きみ子 室伏 カルバ環状ホスファチジン酸誘導体
US8101552B2 (en) * 2005-03-14 2012-01-24 Yeda Research And Development Company Ltd. Cyclic phosphates as plant growth regulators
ES2518371T3 (es) * 2006-04-26 2014-11-05 Toyama Chemical Co., Ltd. Inductor de la neurogénesis o agente terapéutico para la neuropatía que comprende un derivado de éter alquílico o una sal del mismo
KR20090097943A (ko) * 2006-12-28 2009-09-16 오짜노미즈 유니버시티 환상 포스파티딘산 유도체를 포함하는 진통제
EP2389348B1 (en) * 2009-01-09 2017-11-15 Sigma-Aldrich Co. LLC Process for the synthesis of beta glycerol phosphate
WO2011065480A1 (ja) * 2009-11-26 2011-06-03 国立大学法人お茶の水女子大学 神経細胞死抑制剤
WO2014115885A1 (ja) 2013-01-28 2014-07-31 国立大学法人お茶の水女子大学 脱髄疾患治療薬
EP2807925A1 (en) * 2013-05-26 2014-12-03 Symrise AG Antimicrobial compositions
EP3386995A1 (en) * 2015-12-08 2018-10-17 Retrophin, Inc. Cyclic phosphates and cyclic phosphoramidates for the treatment of neurologic disorders

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL63037A (en) * 1981-06-04 1985-12-31 Israel State Dioxaphosphorinanes,their preparation and pharmaceutical and veterinary compositions containing them
US5565439A (en) * 1992-11-24 1996-10-15 The Procter & Gamble Company Methods of using lysophosphatidic acid for treating hyperproliferative conditions
JPH06228169A (ja) * 1993-02-05 1994-08-16 Sagami Chem Res Center １−ｏ−アシルグリセロール２，３−ホスフェートの製造法
JPH07149772A (ja) * 1993-11-26 1995-06-13 Sagami Chem Res Center タンパク質リン酸化酵素ｃの活性促進剤
JPH07258278A (ja) * 1994-03-18 1995-10-09 Sagami Chem Res Center １−Ｏ−アシルグリセロール−２，３−ホスフェート誘導体を有効成分とするＤＮＡポリメラーゼαの阻害剤
JPH0925235A (ja) * 1995-07-13 1997-01-28 Sagami Chem Res Center １−ｏ−アシルグリセロール−２，３−ホスフェート誘導体を有効成分とするがん転移抑制剤
US6150345A (en) * 1998-08-10 2000-11-21 Regents Of The University Of California Methods for promoting survival of myelin producing cells
IL129179A0 (en) 1999-03-25 2000-02-17 Yeda Res & Dev Cyclic glycerophosphates and analogs thereof

Also Published As

Publication number Publication date
RU2247557C2 (ru) 2005-03-10
AU3451700A (en) 2000-10-16
WO2000057865A9 (en) 2001-11-15
CN1348375A (zh) 2002-05-08
EP1162959B1 (en) 2005-03-09
NZ514525A (en) 2003-10-31
MXPA01009650A (es) 2002-07-02
AU768911B2 (en) 2004-01-08
WO2000057865A3 (en) 2001-06-28
JP2002540146A (ja) 2002-11-26
BR0009296A (pt) 2001-12-18
HK1042038A1 (zh) 2002-08-02
DE60018554D1 (de) 2005-04-14
US6914056B1 (en) 2005-07-05
WO2000057865A2 (en) 2000-10-05
CA2368597A1 (en) 2000-10-05
EP1162959A2 (en) 2001-12-19
KR20010112364A (ko) 2001-12-20
ATE290385T1 (de) 2005-03-15
IL129178A0 (en) 2000-02-17

Similar Documents

Publication Publication Date Title
DE69433560T2 (de) Valproinsäure kovalent gebunden an einem lysophospholipid
DE68928920T2 (de) Fettsäure-arzneimittel-konjugat zur verabreichung von arzneimitteln durch die blut-gehirn-schranke
DE3417857C2 (de) Nicht-liposomales pharmazeutisches Mittel
DE60124240T2 (de) Pyrophosphate zur erhöhung der zellfunktion durch schutz von muscarinrezeptoren
DE69910560T2 (de) Wasserlöslische prodrugs von 2,6-diisopropylphenol-analoga
DE69937198T2 (de) Behandlung der alzheimer-krankheit durch erhöhung des cytidin-spiegels in vivo
DE60100055T2 (de) Neue Verwendung einer Klasse von Peptidverbindungen zur Behandlung von Allodynie oder andere Arten von chronischen oder Phantomschmerzen
DE68913756T2 (de) In vivo cytoprotektiv wirkende neurotrope alkohole.
US6914056B1 (en) Pharmaceutical compositions comprising cyclic glycerophosphates and analogs thereof for promoting neural cell differentiation
DE3805744C2 (de) Phenylcarbamate zur Hemmung der Acetylcholinesterase
DE3201865C2 (de) Verwendung von 6-Amino-1-hydroxyhexan-1,1- diphosphonsäure und Derivaten davon zur Behandlung der Osteopathie
EP1064002B1 (de) Verwendung von sphingosin-1-phosphat, sphingosin-1-phosphat-derivaten und/oder deren gemische zur behandlung von entzündlichen hautkrankheiten
DE60305485T2 (de) Neue therapeutische verwendung des ribosid von 5-aminoimidazol-4- carbonsäureamid (acadesin)
WO1996030003A1 (de) Arzneistoffe zur selektiven bekämpfung von tumorgewebe
WO1997011694A1 (de) Kreatin zum schutz von neuralem gewebe
DE60029979T2 (de) Liposomen-Formulierung der Verbindung 6,9-BIS-[(2-aminoethyl)benzo[g]isochinolin-5,10-dionidimaleat
DE60024969T2 (de) 2-methyl-3-butenyl-1-pyrophosphorsäuresalze und mittel zur behandlung von lymphozyten
EP1486487A1 (de) An 4-Stellung substituierte 2-Pyrrolidinon-Derivate zur Verringerung des extrazellulären Glutamat-Spiegels
DE60125420T2 (de) Zusammensetzungen enthaltend phospholipase c inhibitoren und verfahren zur erhöhung parazellulärer permeabilität der epithelbarriere und endothelbarriere
DE60117770T2 (de) Cholinderivate zur behandlung der alzheimerkrankheit
DE19738484A1 (de) Verwendung von N-Propanoyl-Mannosamin als Medikament
Heckmann Beitrag zur Elektromyographie in der Veterinärmedizin
DE3820817A1 (de) Antileptikum
Monnier Biochemische, pharmakologische und humorale Aspekte des Schlaf-Wachseins
EP2066314A2 (de) Verwendung von theogallin zur behandlung von mentalen konzentrationsleistungsstörungen, drepression und demenz

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee